VenoStent
PrivateLast Round
Seed Round
Apr 10, 2026
Total Funding Raised
$32.22M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
VenoStent operates in Healthcare & Life Sciences and is based in Houston, Texas. Its latest recorded funding round was a Series A Extension round in June 2024.
VenoStent is a medical device company that develops bioabsorbable vascular wraps to improve outcomes for hemodialysis patients.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Advanced Materials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VenoStent Comparables
Compare VenoStent with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Laminate Medical Technologies | 92% | |
| Amplifi Vascular, Inc. | 90% | |
| Phraxis, Inc. | 78% |
For institutional investors. Book with your work email.
VenoStent Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Apr 10, 2026 | ||||
| Series A Extension | Jun 27, 2024 | ||||
| Grant | Jun 27, 2024 | ||||
| Series A | Jul 31, 2023 | ||||
| Seed | Feb 23, 2021 | ||||
SAFE | Jun 24, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
VenoStent Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Olima Ventures | Seed |
| Good Growth Capital | Series A, Series A Extension |
| IAG Capital Partners | Seed, Series A, Series A Extension |
| NIH RADx | Grant |
| Creative Ventures | Series A, Seed |
| SNR | Series A |
| Norwest Venture Partners | Series A, Series A Extension |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 31% MoM, reaching 5.2K.
- Aug 2, 2026
Grew 15% QoQ, from 33 to 38 employees.
For institutional investors. Book with your work email.
VenoStent Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about VenoStent's valuation, stock price, and market status.
Is VenoStent a public or private company?
VenoStent is a private company.
What is the current stock price of VenoStent?
VenoStent is a private company, so its shares have no public market price. Caplight tracks VenoStent's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is VenoStent worth (valuation)?
Valuation information for VenoStent is not publicly available.
Can I buy VenoStent stock?
VenoStent shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was VenoStent's last funding round?
VenoStent's most recent funding round was Seed Round on April 10, 2026.
Who are the main investors in VenoStent?
Key investors in VenoStent include Good Growth Capital, IAG Capital Partners, Creative Ventures, Norwest Venture Partners, Texas Halo Fund.
Will VenoStent IPO soon?
No public IPO plans have been announced for VenoStent.
How can I track VenoStent secondary market activity?
Caplight tracks bids, offers, and trades in VenoStent's shares on secondary markets.